Eli Lilly's New Obesity Drug Data Sparks Stock Rise Amid Broad Bullish Outlook

SentiSense · Published · Updated

Eli Lilly will present fresh Phase 3 data on its oral GLP-1 orforglipron and on retatrutide at a European conference, and Berenberg frames the setup a...

Sign in to read the full story. Free accounts include 20 full reads a month.

Sign in or create a free account

Powered by SentiSense - Intelligent Market Analysis